10-Q: WEED, Inc. Faces Going Concern Amidst Mounting Losses

WEED, Inc. reported no revenue and a significant increase in comprehensive loss for the first half of 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• WEED, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with prior periods.
• The company's comprehensive loss increased significantly to $(546,884) for the six months ended June 30, 2025, compared to $(282,392) for the same period in 2024.
• Net operating loss for the six months ended June 30, 2025, was $(528,782), a substantial increase from $(315,008) in the prior year period.
• Cash on hand decreased dramatically to $5,350 as of June 30, 2025, from $159,355 at December 31, 2024.
• Total current assets fell to $18,482 from $189,891, while total current liabilities increased to $996,833 from $959,372 over the same period.
• The company reported a negative working capital of $978,351 and an accumulated deficit of $85,451,350 as of June 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without securing additional financing.
• General and administrative expenses increased by $225,459 to $447,320 for the six months ended June 30, 2025, primarily due to increases in consulting and services salary.
• Interest expense surged to $(19,289) for the six months ended June 30, 2025, from $(1,198) in the prior year, mainly due to notes payable from related parties.
• 10,500,000 shares of common stock valued at $300,000 and an additional 500,000 shares valued at $15,000 were issued for services during the six months ended June 30, 2025.

Sentiment

Score: 1

Explanation: The company exhibits severe financial distress with no revenue, substantial and increasing losses, a critical 'going concern' warning, and rapidly depleting cash reserves. Key projects are stalled due to lack of funding, and internal controls are deemed ineffective. This indicates an extremely negative outlook.

Positives

• Net operating loss for the three months ended June 30, 2025, decreased to $(94,045) from $(144,955) in the prior year, indicating a reduction in operational expenses for the quarter.
• Net cash used in operating activities for the six months ended June 30, 2025, improved to $(70,519) compared to $(259,451) for the same period in 2024, primarily due to estimated fair value of stock-based compensation and shares issued for services.

Negatives

• The company has generated no revenue since its inception, indicating a lack of core business operations or market penetration.
• Comprehensive loss for the six months ended June 30, 2025, significantly increased to $(546,884) from $(282,392) in the prior year.
• Cash on hand plummeted by over 96% from $159,355 at December 31, 2024, to $5,350 at June 30, 2025.
• Total current assets decreased by over 90% to $18,482, while total current liabilities increased, resulting in a worsening negative working capital position of $978,351.
• The accumulated deficit grew to $85,451,350, and stockholders' equity remained negative at $(447,927).
• Interest expense increased significantly due to related party notes payable, reflecting increased reliance on debt.
• The company's disclosure controls and procedures were deemed not effective as of June 30, 2025, citing the lack of an audit committee, one individual serving as CEO/CFO, and no formal processes for related party transactions.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to no revenues, continuous net losses, an accumulated deficit of $85,451,350, and negative working capital of $978,351.
• The company is entirely dependent on securing additional equity and/or debt financing to fund short-term operations, with no assurances of success.
• Key projects, including Sangre's Cannabis Genomic Study and WEED Israel's clinical trials and patent acquisition, are on hold due to insufficient funding.
• Disclosure controls and procedures are not effective, increasing the risk of material misstatements or undetected issues.
• The absence of an audit committee and the dual role of CEO/CFO by a single individual (Glenn E. Martin) pose significant corporate governance risks.
• Lack of formal processes for identifying and approving related party transactions creates potential for conflicts of interest and financial irregularities.
• Professional fees are expected to vary and could substantially increase with unusual transactions like acquisitions or securities offerings, further straining liquidity.
• The company does not anticipate satisfying cash needs from revenues for many years to come, indicating a prolonged period of reliance on external funding.

Future Outlook

The company plans to pursue various business opportunities in the cannabis and hemp field, including indoor/outdoor grows, cultivation, research, product development, and services globally. Long-term goals include becoming a 'True Seed-to-Sale' global holding company providing infrastructure, financial solutions, product development, and real estate options. The New York property is conceptually planned for a 'Cannabis Friendly' luxury condos and resort development, but no funding or detailed plans have been developed. The company intends to make its brand global and seek opportunities for international research, marketing, import/export, and manufacturing of proprietary products. However, the company does not expect to generate sufficient revenues to meet its cash needs for many years and is actively seeking additional financing to fund these initiatives and ongoing operations.

Management Comments

• Management is actively pursuing new products and services to begin generating revenues.
• The company is currently seeking additional sources of capital to fund short term operations.
• We will need additional financing to attempt to accomplish these goals.
• No work is being conducted now until further funds are available (referring to Sangre's Cannabis Genomic Study and WEED Israel's patent acquisition/clinical trials).
• We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.
• Based on our lack of revenues, our cash on hand and current monthly burn rate of approximately $52,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.
• As funds become available to us, we expect to implement additional measures to improve disclosure controls and procedures.

Industry Context

WEED, Inc. operates in the rapidly evolving global cannabis and hemp industry, which is characterized by complex regulatory landscapes, significant capital requirements, and intense competition. While the company has outlined ambitious plans for cultivation, research, product development, and real estate in this sector, its current financial state—marked by zero revenue and substantial losses—places it far behind established players and even many emerging companies that have successfully secured initial market traction and funding. The company's focus on 'Seed-to-Sale' and genomic research aligns with high-value segments of the industry, but the inability to fund these initiatives means it is not currently participating meaningfully in these trends. The mention of 37 states approving medical cannabis and 17 states approving adult-use cannabis in the USA highlights the growing market potential, yet WEED, Inc. has not capitalized on this expansion.

Comparison to Industry Standards

• The company's complete lack of revenue stands in stark contrast to operational cannabis and hemp companies, many of which are generating millions or billions in annual sales, such as Canopy Growth, Tilray, or Curaleaf.
• WEED, Inc.'s accumulated deficit of over $85 million and negative working capital of nearly $1 million are significantly worse than industry benchmarks, where profitable or cash-flow positive operations are increasingly expected, especially from larger, publicly traded entities.
• The 'going concern' warning is a critical red flag, indicating severe financial distress, which is not typical for healthy companies in the cannabis sector or any industry.
• The company's cash balance of $5,350 is negligible compared to the capital reserves typically held by even small-cap companies in the cannabis industry, which often require substantial funds for cultivation, processing, and regulatory compliance.
• The ineffectiveness of disclosure controls and procedures, coupled with the lack of an audit committee and the CEO/CFO dual role, falls significantly below corporate governance standards expected of publicly traded companies, regardless of industry.

Corporate Governance

Legal Proceedings

• Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

Related Party Transactions

• Notes payable to related parties totaled $345,455 as of June 30, 2025.
• Glenn Martin (officer) provided advances totaling $305,000 (2024) and $47,000 (2025), with repayments of $130,000 in January 2025. The outstanding balance from Glenn Martin is $220,000.
• Jeffrey Miller (executive officer) is owed $120,000 via a non-interest-bearing note payable related to the Hempirical Genetics, LLC acquisition.
• Nicole M. Breen receives $8,000 a month in cash compensation for services.
• Glenn E. Martin receives $7,000 a month in cash compensation for services.
• Accrued officer compensation, including for related parties, increased to $281,250 as of June 30, 2025.
• Imputed interest on related party loans was $7,337 for the six months ended June 30, 2025.
• 10,500,000 shares of common stock valued at $300,000 and 500,000 shares valued at $15,000 were issued to consultants for services during the six months ended June 30, 2025.

Stakeholder Impact

• **Shareholders**: Face significant risk of capital loss due to the company's 'going concern' status, lack of revenue, increasing losses, and rapidly depleting cash. Dilution is a high possibility given the stated need for capital raises through securities sales.
• **Employees/Officers**: Accrued officer compensation has increased, indicating potential delays or non-payment of salaries, which could impact morale and retention. Glenn Martin and Nicole Breen are receiving cash compensation, but other accrued compensation is significant.
• **Creditors**: Related party creditors (like Glenn Martin and Jeffrey Miller) are exposed to repayment risk given the company's financial instability and dependence on future financing.
• **Customers/Partners**: Potential partners or customers for cultivation centers, research, or product development may be deterred by the company's financial instability and the stalled status of key projects like the Cannabis Genomic Study.

Next Steps

• Actively pursue new products and services to begin generating revenues.
• Seek additional sources of capital to fund short-term operations and long-term business goals.
• Secure funding to resume Sangre's Cannabis Genomic Study.
• Secure proper funding to complete the purchase of Professor Touitou's patents and begin clinical trials through WEED Israel Cannabis Ltd.
• Implement additional measures to improve disclosure controls and procedures as funds become available.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by zero revenue, a substantial and increasing comprehensive loss, rapidly dwindling cash reserves ($5,350), and a critical 'going concern' warning. Its accumulated deficit exceeds $85 million, and working capital is deeply negative. Key strategic projects are stalled due to lack of funding, and management explicitly states they do not expect to generate sufficient revenue for many years. Furthermore, the disclosure controls are ineffective, and there are significant corporate governance concerns. The reliance on related party loans and future capital raises in such a precarious financial state presents extreme risk to investors. A seasoned investor would view this as a company with a very high probability of failure or significant dilution, warranting a strong sell recommendation.

Keywords

Cannabis, Hemp, Marijuana, Genetics, Cultivation, Biotechnology, SEC Filing, 10-Q, Financial Report, Going Concern, BUDZ